Therapy of chronic viral hepatitis

Medical Clinics of North America

Volumn 80, Issue 5, 1996, Pages 957-972

  Fried, M W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; DIDANOSINE; FAMCICLOVIR; FIALURIDINE; HEPATITIS B VACCINE; LAMIVUDINE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PARACETAMOL; RIBAVIRIN; RIBOZYME;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOGLOBULINEMIA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG RECEPTOR BINDING; FEVER; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; META ANALYSIS; MULTICENTER STUDY; MYALGIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS HEPATITIS;

EID: 0029758921     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70475-2     Document Type: Article

References (77)

1. A. Alberti G. Realdi Parenterally acquired non-A, non-B (type C) hepatitis N. McIntyre Benhamou J.-P. J. Bircher Oxford Textbook of Clinical Hepatology 1991 Oxford University Press Oxford 605 617
2. M.J. Alter E.E. Mast The epidemiology of viral hepatitis in the United States Gastroenterol Clin North Am 23 1994 437 455
3. 2 production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 19 1993 228 231
4. P. Andreone C. Cursaro A. Gramenzi Pilot study of α-interferon and ketoprofen combined therapy in non-responder patients with chronic hepatitis C: An interim report Gastroenterology 106 1994 859A
5. E. Baudine P. Marcellin M. Pouteau Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C Clin Endocrinol 39 1993 657 661
6. S. Brillanti J. Garson M. Foli A pilot study of combination therapy with ribavirin plus interferon-alfa for interferon-alfa resistant chronic hepatitis C Gastroenterology 107 1994 812 817
7. M.G. Brook P. Karayiannis H.C. Thomas Which patients with chronic hepatitis B infection will respond to α-interferon therapy? A statistical analysis of predictive factors Hepatology 10 1989 761 763
8. J. Bukh R.H. Miller R.H. Purcell Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes Semin Liver Dis 15 1995 41 63
9. J. Camps S. Crisostomo M. Garcia-Granero Prediction of the response of chronic hepatitis C to interferon alfa: A statistical analysis of pretreatment variables Gut 34 1993 1714 1717
10. I. Castillo J. Bartolome S. Navas Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon Hepatology 19 1994 1342 1346
11. X. Causse H. Godinot M. Chevallier Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis Gastroenterology 101 1991 497 502
12. H.S. Conjeevaram J.H. Hoofnagle H.A. Austin Long-term outcome of hepatitis B virus–related glomerulonephritis after therapy with interferon alfa Gastroenterology 109 1995 540 546
13. G.L. Davis L.A. Balart E.R. Schiff Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial N Engl J Med 321 1989 1501 1505
14. A.M. Di Bisceglie H.J. Conjeevaram M.W. Fried Ribavirin as therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 897 903
15. A.M. Di Bisceglie T.L. Fong M.W. Fried A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B Am J Gastroenterol 88 1993 1887 1892
16. A.M. Di Bisceglie P. Martin C. Kassianides Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial N Engl J Med 321 1989 1506 1510
17. J.I. Dienstag R.P. Perrillo E.R. Schiff A preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 333 1995 1657 1661
18. G. Dusheiko J.H. Hoofnagle Hepatitis B N. McIntyre Benhamou J.-P. J. Bircher Oxford Textbook of Clinical Hepatology 1991 Oxford University Press Oxford 571 592
19. C. Ferri F. Greco G. Longombardo Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia Arthritis Rheum 34 1991 1606 1610
20. T.-L. Fong M. Shindo S.M. Feinstone Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C J Clin Invest 88 1991 1058 1060
21. M.W. Fried A.M. Di Bisceglie S.E. Straus FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B Hepatology 16 1992 127A
22. M.W. Fried J.O. Draguesku M. Shindo Clinical and serological differentiation of autoimmune and hepatitis C virus–related chronic hepatitis Dig Dis Sci 1993 631 636
23. M.W. Fried T.-L. Fong M.G. Swain Therapy of chronic hepatitis B with a 6-month course of ribavirin J Hepatol 21 1994 145 150
24. M.W. Fried J.H. Hoofnagle Therapy of hepatitis C Semin Liver Dis 15 1995 82 91
25. M.W. Fried J.C. Korenman A.M. Di Bisceglie A pilot study of 2′, 3′-dideoxyinosine for the treatment of chronic hepatitis B Hepatology 16 1992 861 864
26. E. Hadziyannis M.W. Fried F.S. Nolte Evaluation of two methods for quantitation of hepatitis C virus RNA Hepatology 22 1995 1000A
27. C.J. Healey S. Read J. Kurtz Hepatitis C infection and alpha-interferon therapy in patients with normal transaminases: A pilot study [abstract] Gastroenterology 108 1995 A1082
28. K. Hino S. Sainokami K. Shimoda Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C J Med Virol 42 1994 299 305
29. J.H. Hoofnagle Therapy of acute and chronic viral hepatitis Adv Intern Med 39 1994 241 275
30. J.H. Hoofnagle A.M. Di Bisceglie J.G. Waggoner Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B Gastroenterology 104 1993 1116 1121
31. J.H. Hoofnagle M. Peters K.D. Mullen Randomized controlled trial of recombinant human α-interferon in patients with chronic hepatitis B Gastroenterology 95 1988 1318 1325
32. R.J. Johnson W.G. Couser Hepatitis B infection and renal disease: Clinical, immunopathogenetic, and therapeutic considerations Kidney Int 37 1990 663 676
33. P. Jouet F. Roudot-Thoraval D. Dhumeaux Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis Gastroenterology 106 1994 686 690
34. K. Kanai M. Kako H. Okamoto HCV genotypes in chronic hepatitis C and response to interferon Lancet 339 1992 1543
35. B.E. Korba J.L. Gerin Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication Antiviral Res 19 1992 55 70
36. J. Korenman B. Baker J. Waggoner Long-term remission of chronic hepatitis B after alpha-interferon therapy Ann Intern Med 114 1991 629 634
37. M. Kruger H.L. Tillman C. Trautwein Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation: A pilot study Hepatology 22 1995 449A
38. J.Y.N. Lau G.L. Davis J. Kniffen Significance of serum hepatitis C virus RNA levels in chronic hepatitis C Lancet 341 1993 1501 1504
39. R. Lin E. Roach M. Zimmerman Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates J Hepatol 23 1995 487 496
40. Lisker-Melman M. A.M. Di Bisceglie S.J. Usala Development of thyroid disease during therapy of chronic viral hepatitis with alpha-interferon Gastroenterology 102 1992 2155 2160
41. K. Mahaney V. Tedeschi G. Maertens Genotypic analysis of hepatitis C virus in American patients Hepatology 20 1994 1405 1411
42. P. Marcellin N. Boyer E. Giostra Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France Hepatology 13 1991 393 397
43. P. Martin C. Kassianides J. Korenman 2′, 3′dideoxyinosine and dideoxyguanosine are potent inhibitors of hepadnaviruses in vivo Hepatology 96 1989 A628
44. M. Martinot-Peignoux P. Marcellin M. Pouteau Pretreatment hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent predictors of sustained response to interferon alfa therapy in chronic hepatitis C Hepatology 22 1995 1050 1056
45. W.-J. Mayet G. Hess G. Gerken Treatment of chronic type-B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis Hepatology 10 1989 24 28
46. R. McKenzie M.W. Fried R. Sallie Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B N Engl J Med 333 1995 1099 1105
47. R. Misiani P. Bellavita D. Fenili Interferon alfa-2a in cryoglobulinemia associated with hepatitis C virus N Engl J Med 330 1994 751 756
48. R. Misiani P. Bellavita D. Fenili Hepatitis C virus infection in patients with essential mixed cryoglobulinemia Ann Intern Med 117 1992 573 577
49. H. Mitsuya S. Broder Antiretroviral chemotherapy against human immunodeficiency virus (HIV) infection: Perspective for therapy of hepatitis B virus infection Cancer Detect Prev 14 1989 299 308
50. M. Naito N. Hayashi H. Hagiwara Serum hepatitis C virus RNA quantity and histologic features of hepatitis C virus carriers with persistently normal ALT levels Hepatology 19 1994 871 875
51. J.-L. Nousbaum S. Pol B. Nalpas Hepatitis C virus type 1 b (II) infection in France and Italy Ann Intern Med 122 1995 161 168
52. W.-B. Offensperger H.E. Blum W. Gerok Molecular therapeutic strategies in hepatitis B virus infection Clin Invest 72 1994 737 741
53. R.P. Perrillo E.R. Schiff G.L. Davis A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B N Engl J Med 323 1990 295 301
54. M. Peters Mechanism of action of interferons Semin Liver Dis 9 1989 235
55. S. Pol B. Jaffredo B. Nalpas Predictive value of HCV viremia after 3 months in the monitoring of antiviral therapy Hepatology 20 1994 159A
56. T. Poynard P. Bedossa M. Chevallier A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis N Engl J Med 332 1995 1457 1462
57. T. Poynard V. Leroy M. Cohard Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration Hepatology 22 1995 28A
58. P.F. Renault J.H. Hoofnagle Side effects of alpha interferon Semin Liver Dis 9 1989 273 277
59. P.F. Renault J.H. Hoofnagle Y. Park Psychiatric complications of long-term interferon alpha therapy Arch Intern Med 147 1987 1577 1580
60. 2b Hepatology 18 1993 1300 1305
61. G. Saracco F. Rosina M.R. Torrani Cerenzia A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis J Hepatol 11 1990 S43 S49
62. R. Schvarcz Z.B. Yun A. Sonnerborg Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone J Med Virol 46 1995 43 47
63. M. Shindo K. Arai Y. Sokawa Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α therapy Ann Intern Med 122 1995 586 591
64. M. Shindo A.M. Di Bisceglie L. Cheung Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C Ann Intern Med 115 1991 700 704
65. M. Shindo A.M. Di Bisceglie J.H. Hoofnagle Long-term follow-up of patients with chronic hepatitis C treated with alpha interferon Hepatology 15 1992 1013 1016
66. A.L. Silverman D.L. Piquette C.L. Filipiak Alpha-interferon treatment of HCV RNA patients with normal or near normal ALT levels [abstract] Gastroenterology 108 1995 A1171
67. R.G. Simonetti C. Camma F. Fiorello Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: A case controlled study Ann Intern Med 106 1992 221
68. J. Summers W.S. Mason Replication of the genome of a hepatitis B–like virus by reverse transcription of an RNA intermediate Cell 29 1982 403 415
69. A. Tsubota K. Chayama K. Ikeda Factors predictive of response to interferon-a therapy in hepatitis C virus infection Hepatology 19 1994 1088 1094
70. H. Tsukuma T. Hiyama S. Tanaka Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1993 1797 1801
71. D.H. Van Thiel L. Friedlander S. Fagiuoli Response to interferon-α therapy is influenced by the iron content of the liver J Hepatol 20 1994 410 415
72. V.S. Venkateshan K. Lieberman D.U. Kim Hepatitis B–associated glomerulonephritis: Pathology, pathogenesis, and clinical course Medicine 69 1990 200 216
73. A. Vitiello G. Ishioka H.M. Grey Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection J Clin Invest 95 1995 341 349
74. U. Watanabe E. Hashimoto T. Hisamitsu The risk factor for development of thyroid disease during interferon-α therapy for chronic hepatitis C Am J Gastroenterol 89 1994 399 403
75. D.K.H. Wong A.M. Cheung K. O'Rourke Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis Ann Intern Med 119 1993 312 323
76. T.L. Wright J.Y.N. Lau Clinical aspects of hepatitis B virus infection Lancet 342 1993 1340 1344
77. K. Yoshioka S. Kakumu T. Wakita Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: Relationship to genotypes of hepatitis C virus Hepatology 16 1992 293 299